Omalizumab

Easthope, Stephanie E.; Jarvis, Blair

doi:10.2165/00003495-200161020-00008

Cited by 83 publications

(39 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Omalizumab (Xolair1, Novartis Pharma AG, Basel, Switzerland/Genentech Inc., South San Francisco, CA, USA), a recombinant humanised monoclonal anti-IgE antibody is the first anti-IgE agent to undergo clinical evaluation in the treatment of IgEmediated diseases [12]. Omalizumab stops the allergic cascade by binding to circulating unbound "free" IgE [13].…”

mentioning

confidence: 99%

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

Buhl¹,

Solèr²,

Matz³

et al. 2002

Eur Respir J

165

136

View full text Add to dashboard Cite

The ability of omalizumab, an anti-immnoglobulin-E agent, to maintain long-term disease control in patients with moderate-to-severe allergic asthma was investigated in a 24-week double-blind extension to a 28-week core trial.During the extension, 483 of the initial 546 patients were maintained on randomised treatment and the lowest sustainable dose of beclomethasone dipropionate (BDP) as established during the steroid-reduction phase of the core trial. The use of concomitant asthma medication was permitted and investigators were allowed to adjust the BDP dose or switch patients from BDP to other asthma medications if deemed necessary.More omalizumab-treated patients (33.5%) than placebo-treated patients (13.5%) were able to complete the extension period without requiring inhaled corticosteroid treatment. The mean BDP equivalent dose throughout the extension was lower in the omalizumab group (25 mg?day -1 ) than in the placebo group (43 mg?day -1 ). Disease control was sustained in 76% of omalizumab patients compared with 59.4% of placebo patients free from an asthma exacerbation during the extension period. Compared with placebo, fewer patients in the omalizumab group used other concomitant asthma medication during the extension. Treatment with omalizumab was well tolerated and the incidence of adverse events was similar between groups.In conclusion, these results suggest that omalizumab is a promising new agent for the long-term control of allergic asthma. Eur Respir J 2002; 20: 73-78.

show abstract

mentioning

confidence: 99%

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

Buhl¹,

Solèr²,

Matz³

et al. 2002

Eur Respir J

165

136

View full text Add to dashboard Cite

show abstract

“…Omalizumab is the first anti-IgE agent to undergo clinical evaluation in the treatment of IgE-mediated diseases [12]. A recombinant humanised monoclonal anti-IgE antibody [13], omalizumab forms complexes with circulating free IgE and prevents it binding to high-and low-affinity receptors on effector cells, thereby inhibiting allergen-induced activation [14][15][16].…”

mentioning

confidence: 99%

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma

Buhl¹,

Hanf²,

Solèr³

et al. 2002

Eur Respir J

138

View full text Add to dashboard Cite

The aim of the present study was to determine the effect of treatment with omalizumab, an anti-immunoglobulin E antibody, on asthma-related quality of life (AQoL) in patients with moderate-to-severe allergic asthma.A total of 546 patients with allergic asthma were randomised to double-blind subcutaneous treatment with either placebo or omalizumab for 52 weeks. A constant beclomethasone dipropionate dose was maintained during the first 16 weeks (steroidstable phase). This was followed by a 12-week steroid-reduction phase. The core study was followed by a 24-week double-blind extension phase. AQoL was evaluated at baseline and at the end of the steroid-stable (week 16), steroid-reduction (week 28) and extension phases (week 52) using the Juniper Asthma Quality of Life Questionnaire (AQLQ).Baseline AQLQ scores were comparable for the two treatment groups. Relative to placebo, omalizumab-treated patients demonstrated statistically significant improvements from baseline across all four AQLQ domains, as well as overall AQoL score, at weeks 16 (except environmental exposure), 28 and 52. Patients on omalizumab were also more likely to achieve clinically significant improvements in AQoL during the course of the study. Overall, almost 70% of patients and investigators rated treatment with omalizumab as "excellent/good", compared with y40% of placebo recipients.Clinical studies show that omalizumab enhances disease control whilst reducing corticosteroid consumption in patients with allergic asthma. The results of the present study show that these changes are paralleled by improvements in asthma-related quality of life that are meaningful to such patients.

show abstract

“…This may be reflected by the occasional induction of mild urticaria, for example, by administration of the therapeutic anti-IgE Ab omalizumab, which complexes IgE and prevents its binding to Fc⑀RI␣ (49). Additional mechanisms protecting from autoreactivity to Fc⑀RI␣ may include antiidiotypic Abs to the anti-Fc⑀RI␣ Abs.…”

Section: Discussionmentioning

confidence: 99%

“…Hexosaminidase release was relatively strong and was dose dependent up to 16% of the total intracellular content with 4% spontaneous release. A negative control isotypematched nonanaphylactogenic Ab, omalizumab (48,49), showed 6% secretion.…”

Section: Figurementioning

confidence: 99%

A High-Affinity Natural Autoantibody from Human Cord Blood Defines a Physiologically Relevant Epitope on the FcεRIα

Bobrzynski

Fux

Vogel

et al. 2005

The Journal of Immunology

View full text Add to dashboard Cite

Natural Abs represent the indigenous immune repertoire and are thus present at birth and persist throughout life. Previously, human autoantibodies to the α domain of the high-affinity IgE receptor (FcεRIα) have been isolated from Ab libraries derived from normal donors and patients with chronic urticaria. To investigate whether these anti-FcεRIα Abs are present in the germline repertoire, we constructed a phage Fab display library from human cord blood, which represents the naive immune repertoire before exposure to exogenous Ags. All isolated clones specific to the FcεRIα had the same sequence. This single IgM Ab, named CBMα8, was strictly in germline configuration and had high affinity and functional in vitro anaphylactogenic activity. Inhibition experiments indicated an overlapping epitope on the FcεRIα recognized by both CBMα8 and the previously isolated anti-FcεRIα Abs from autoimmune and healthy donors. This common epitope on FcεRIα coincides with the binding site for IgE. Affinity measurements demonstrated the presence of Abs showing CBMα8-like specificity, but with a significantly lower affinity in i.v. Ig, a therapeutic multidonor IgG preparation. We propose a hypothesis of escape mutants, whereby the resulting lower affinity IgG anti-FcεRIα Abs are rendered less likely to compete with IgE for binding to FcεRIα.

show abstract

Omalizumab

Cited by 83 publications

References 11 publications

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma

A High-Affinity Natural Autoantibody from Human Cord Blood Defines a Physiologically Relevant Epitope on the FcεRIα

Contact Info

Product

Resources

About